<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Induction of Resistance to Targeted Therapies in Patient-Derived Xenograft Models

Oncogene activating mutations have been found to be oncogenic drivers in many different cancers, such as EGFR L858R mutation, EML4-‐ALK fusion (1, 2), CCDC6-RET or NCOA4-RET fusions (3), RSPO2,3 fusions, and c-‐met gene amplifications (4) in NSCLC (2, 5), CRC, gastric adenocarcinoma, etc.